The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Transplantation and cell therapy highlights at COSTEM 2022
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides his highlights from the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), including debates surrounding transplantation versus CAR-Ts in myeloma and lymphoma, the role of measurable residual disease (MRD) in acute myeloid leukemia (AML), maintenance therapy in FLT3-positive AML, and developments in natural killer (NK) cells. This interview took place at COSTEM 2022 in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
